
US Regulators to Decide on Peptide Availability Amid Safety Concerns and Popularity Boom
US Food and Drug Administration's advisory committee will meet to decide if seven peptides, marketed for various wellness treatments, can be compounded by licensed pharmacies. The review comes amid soaring popularity, safety concerns from the FDA, and controversy over committee members' ties to peptide businesses.














